Menu
GWAS Study

Genetic landscape of chronic obstructive pulmonary disease identifies heterogeneous cell-type and phenotype associations.

Sakornsakolpat P, Prokopenko D, Lamontagne M et al.

30804561 PubMed ID
GWAS Study Type
257811 Participants
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

SP
Sakornsakolpat P
PD
Prokopenko D
LM
Lamontagne M
RN
Reeve NF
GA
Guyatt AL
JV
Jackson VE
SN
Shrine N
QD
Qiao D
BT
Bartz TM
KD
Kim DK
LM
Lee MK
LJ
Latourelle JC
LX
Li X
MJ
Morrow JD
OM
Obeidat M
WA
Wyss AB
BP
Bakke P
BR
Barr RG
BT
Beaty TH
BS
Belinsky SA
BG
Brusselle GG
CJ
Crapo JD
DJ
de Jong K
DD
DeMeo DL
FT
Fingerlin TE
GS
Gharib SA
GA
Gulsvik A
HI
Hall IP
HJ
Hokanson JE
KW
Kim WJ
LD
Lomas DA
LS
London SJ
MD
Meyers DA
OG
O'Connor GT
RS
Rennard SI
SD
Schwartz DA
SP
Sliwinski P
SD
Sparrow D
SD
Strachan DP
TR
Tal-Singer R
TY
Tesfaigzi Y
VJ
Vestbo J
VJ
Vonk JM
YJ
Yim JJ
ZX
Zhou X
BY
Bossé Y
MA
Manichaikul A
LL
Lahousse L
SE
Silverman EK
BH
Boezen HM
WL
Wain LV
TM
Tobin MD
HB
Hobbs BD
CM
Cho MH
Chapter II

Abstract

Summary of the research findings

Chronic obstructive pulmonary disease (COPD) is the leading cause of respiratory mortality worldwide. Genetic risk loci provide new insights into disease pathogenesis. We performed a genome-wide association study in 35,735 cases and 222,076 controls from the UK Biobank and additional studies from the International COPD Genetics Consortium. We identified 82 loci associated with P < 5 × 10-8; 47 of these were previously described in association with either COPD or population-based measures of lung function. Of the remaining 35 new loci, 13 were associated with lung function in 79,055 individuals from the SpiroMeta consortium. Using gene expression and regulation data, we identified functional enrichment of COPD risk loci in lung tissue, smooth muscle, and several lung cell types. We found 14 COPD loci shared with either asthma or pulmonary fibrosis. COPD genetic risk loci clustered into groups based on associations with quantitative imaging features and comorbidities. Our analyses provide further support for the genetic susceptibility and heterogeneity of COPD.

35,735 cases, 222,076 controls

Chapter III

Study Statistics

Key metrics and study information

257811
Total Participants
GWAS
Study Type
No
Replicated
European, East Asian, African American or Afro-Caribbean, Hispanic or Latin American, NR
Ancestry
Canada, U.S., Netherlands, Republic of Korea, Poland, Norway, U.K.
Recruitment Country
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.